Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 1,369

The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.

Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients

Open access
Kumar, S K, Dispenzieri, A, Lacy, M Q, Gertz, M A, Buadi, F K, Pandey, S, Kapoor, P, Dingli, D, Hayman, S R, Leung, N, Lust, J, McCurdy, A, Russell, S J, Zeldenrust, S R, Kyle, R A, Rajkumar, S V · 2014 · Leukemia

Abstract

Therapy for multiple myeloma (MM) has markedly changed in the past decade with the introduction of new drugs, but it is not clear whether the improvements have been sustained. We studied 1038 patients diagnosed between 2001 and 2010, grouping patients into two 5-year periods by diagnosis, 2001–2005 and 2006–2010. The median estimated follow-up for the cohort was 5.9 years with 47% alive at the last follow-up. The median overall survival (OS) for the entire cohort was 5.2 years: 4.6 years for patients in the 2001–2005 group compared with 6.1 years for the 2006–2010 cohort (P=0.002). The improvement was primarily seen among patients over 65 years, the 6-year OS improving from 31 to 56%, P<0.001. Only 10% of patients died during the first year in the latter group, compared with 16% in the earlier cohort (P<0.01), suggesting improvement in early mortality. The improved outcomes were linked closely to the use of one or more new agents in initial therapy. The current results confirm continued survival improvement in MM and highlight the impact of initial therapy with novel agents. Most importantly, we demonstrate that the improved survival is benefitting older patients and that early mortality in this disease has reduced considerably.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/leu.2013.313

Cites

40 of 40 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 3

  1. Greipp PR, Kumar S . Plasma cell labeling index. Methods Mol Med 2005; 113: 25–35.
  2. Moreau P, Planche L, Attal M, Hulin C, Facon T, Caillot D et al. The combination of ISS 3, high LDH and t(4;14) and/or Del(17p) identify a simple prognostic index for overall survival in patients treated with novel agents-based induction therapy and front-line autologous stem cell transplantation, and allow the definition of a subgroup of patients at high-risk of early death from progressive disease. ASH Ann Meeting Abstr 2012; 120: 598.
  3. Kapoor P, Kumar S, Mandrekar SJ, Laumann KM, Dispenzieri A, Lacy MQ et al. Efficacy of thalidomide- or lenalidomide-based therapy in proliferative multiple myeloma. Leukemia 2011; 25: 1195–1197. · doi:10.1038/leu.2011.54

Cited by

See all 1,369

Metadata

Authors
Kumar, S. K., Dispenzieri, A., Lacy, M. Q., Gertz, M. A., Buadi, F. K., Pandey, S., Kapoor, P., Dingli, D., Hayman, S. R., Leung, N., Lust, J., McCurdy, A., Russell, S. J., Zeldenrust, S. R., Kyle, R. A., & Rajkumar, S. V.
Venue
Leukemia
Published
2013-10-25
Volume
28
Issue
5
Pages
1122-1128
ISSN
  • 0887-6924 (ISSN-L)
  • 1476-5551
OpenAlex
W2020298011
Cited by
1,369
References
40
FWCI
51.83
Type
journal article
Language
en
Open access
green
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.